A phase II open-label study of ONC201 in | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 2

5 participants needed

1 Location

Brief description of study

This is A phase II, open-label study of ONC201 in adults with recurrent high- grade glioma. Subjects will be age 18 or older with a histone H3 K27M mutant glioma that has progressed after radiation therapy. The primary objective is to estimate the overall response rate (ORR) of ONC201 in this population. In addition, secondary objects will be to assess the safety, toxicities and tolerability of ONC201 in adults with recurrent high-grade glioma and estimate the median PFS, PFS at 2 and 6 months (progression-free survival at 6 months), median OS, and median duration of response. This study is sponsor by Oncoceutics, INC

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 09 Apr 2021. Study ID: 832987

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A phase II open-label study of ONC201 in adults with recurrent high-grade glioma

Brief description of study

Eligibility of study

Find a site